RxDoctor Payments Data

Luis Herrera, MD

Family Medicine · Srping Hill, FLNPI 1124077003

Payments from drug & device makers

$1,800in general payments, 2019–2025

Across 26 payments — averaging $69.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$588
  • Bayer$337
  • Novo Nordisk$335
  • Johnson & Johnson$308
  • Boehringer Ingelheim$125
  • GSK$62
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca10$588
Bayer3$337
Novo Nordisk3$335
Johnson & Johnson(3 entities)4$308
Boehringer Ingelheim1$125
GSK3$62
Lilly USA, LLC1$29
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,800 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,830
Medicare patients
74
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$56,076
EliquisApixaban51$45,323
OzempicSemaglutide31$29,386
TrulicityDulaglutide22$29,204
JanuviaSitagliptin Phosphate17$21,045
XareltoRivaroxaban18$16,076
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,523
LinzessLinaclotide23$12,602
SymbicortBudesonide/Formoterol Fumarate22$6,579
FarxigaDapagliflozin Propanediol12$6,490
Breo ElliptaFluticasone/Vilanterol15$6,261
Levemir FlexpenInsulin Detemir21$5,201
Novolog FlexpenInsulin Aspart15$4,333
LevemirInsulin Detemir13$4,237
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$56,07651 claims
Novo NordiskOzempic, Levemir$335$33,62344 claims
Lilly USA, LLCTrulicity$29$29,20422 claims
GSKTrelegy Ellipta, Breo Ellipta$62$21,78439 claims
Johnson & JohnsonXarelto$308$16,07618 claims
AstraZenecaSymbicort, Farxiga$588$13,06934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Srping Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →